Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.
What is Multiple Myeloma?

Multiple myeloma is a form of cancer that affects the bone marrow. The cancer is also called Kahler’s disease, named after an Austrian pathologist called Otto Kahler who first described the condition.

Read More

Overview

Feature Articles

Latest Multiple Myeloma News and Research

Metabolic vulnerabilities in malignant cells may lead to new breast cancer therapies

Metabolic vulnerabilities in malignant cells may lead to new breast cancer therapies

Efficacy of COVID-19 convalescent plasma therapy in patients with hematological malignancies and COVID-19

Efficacy of COVID-19 convalescent plasma therapy in patients with hematological malignancies and COVID-19

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

COVID-19 vaccines offer protection for multiple myeloma patients, but lesser than other cancer survivors

COVID-19 vaccines offer protection for multiple myeloma patients, but lesser than other cancer survivors

Large study reveals increased rates of myeloma precursor condition in high-risk groups

Large study reveals increased rates of myeloma precursor condition in high-risk groups

Potentially serious side effect reported after CAR-T cell therapy for multiple myeloma

Potentially serious side effect reported after CAR-T cell therapy for multiple myeloma

NYU Langone opens new state-of-the-art center to treat patients with blood cancers

NYU Langone opens new state-of-the-art center to treat patients with blood cancers

Combination of two targeted drugs shows "clinically meaningful" activity in some malignant brain tumors

Combination of two targeted drugs shows "clinically meaningful" activity in some malignant brain tumors

Study shows vaccinated multiple myeloma patients at greater risk of breakthrough SARS-CoV-2 infections

Study shows vaccinated multiple myeloma patients at greater risk of breakthrough SARS-CoV-2 infections

Exosomes involved in the progression of breast cancer in patients with obesity, diabetes

Exosomes involved in the progression of breast cancer in patients with obesity, diabetes

Red blood cell distribution width as a biomarker for COVID-19

Red blood cell distribution width as a biomarker for COVID-19

Researchers identify never-before-defined subtypes of a blood cancer

Researchers identify never-before-defined subtypes of a blood cancer

Washington University School of Medicine receives $17 million to address disparities in cancers

Washington University School of Medicine receives $17 million to address disparities in cancers

Despite restraints, democrats’ drug pricing plan could still aid consumers

Despite restraints, democrats’ drug pricing plan could still aid consumers

What do we really know about vaccine effectiveness?

What do we really know about vaccine effectiveness?

COVID-19 vaccine-elicited immune responses in myeloma patients

COVID-19 vaccine-elicited immune responses in myeloma patients

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines